Cipla Q4 Results FY24-25: Net Profit Rises 30% to Rs.1,222 Cr; Announces Rs.16 Dividend

Cipla Ltd. reported a strong financial performance in Q4 FY24-25, posting a 30% year-on-year rise in net profit to Rs.1,222 crore, compared to Rs.939 crore in the same quarter last year. Revenue from operations stood at Rs.6,597.72 crore, marking an 8.45% increase from Rs.6,082.37 crore in Q4 FY24.

Key Highlights

Revenue: Rs.6,597.72 crore, up 8.45% YoY from Rs.6,082.37 crore

Net Profit: Rs.1,222 crore, up 30% YoY from Rs.939 crore

EBITDA: Rs.1,537 crore, up 16.8% YoY from Rs.1,316 crore

Total Dividend: Rs.16 per share (Final: Rs.13 + Special: Rs.3)

Cipla Ltd

Trade

1413.914.70 (1.05 %)

Updated - 25 May 2026
1420.00day high
DAY HIGH
1398.50day low
DAY LOW
668915
VOLUME (BSE)

Quarterly – Cipla Q4 Results FY24-25

Cipla closed the financial year with a strong Q4 showing, delivering healthy gains in profitability and topline growth. The 30% rise in net profit was driven by solid operational performance and improved EBITDA, which rose to Rs.1,537 crore. Revenue growth was supported by continued demand across key markets and an expanding portfolio.

The company's board declared a total dividend of Rs.16 per share, including a Rs.3 special dividend. The record date has been set for 27 June 2025, with the payout scheduled within 30 days of the annual general meeting.

Segment Highlights

Cipla’s core pharmaceuticals segment generated Rs.6,503.63 crore in Q4 FY25, rising from Rs.5,996.38 crore in the year-ago period. Revenue from new ventures stood at Rs.288.48 crore, reflecting a strong 35.4% YoY growth from Rs.212.99 crore.

This balanced growth across legacy operations and emerging segments highlights Cipla’s multi-channel revenue approach, ensuring long-term scalability and margin expansion.

Sector Expectations for Cipla Q4 Results FY24-25 

The pharma industry projected moderate earnings growth in Q4 FY25. Cipla outperformed sector averages, particularly in profitability, backed by efficient cost controls and segment expansion. The strong dividend payout further underlines the company’s confidence in future earnings stability and shareholder returns.

Cipla – Consolidated Financial Performance (Q4 FY24-25)

Metric

Q4 FY24-25

Q4 FY23-24

YoY Change (%)

Revenue from Operations

Rs.6,597.72 crore

Rs.6,082.37 crore

+8.45%

EBITDA

Rs.1,537 crore

Rs.1,316 crore

+16.8%

Net Profit (PAT)

Rs.1,222 crore

Rs.939 crore

+30.1%

Pharma Segment Revenue

Rs.6,503.63 crore

Rs.5,996.38 crore

+8.47%

New Ventures Revenue

Rs.288.48 crore

Rs.212.99 crore

+35.4%

Dividend (Total)

Rs.16 per share

For a complete overview of all upcoming and past earnings reports, check the Quarterly Results Calendar 2025.

Source: Cipla Ltd – Board Meeting Outcome and Audited Q4 FY25 Financial Results

Share this article: 

Published Date : 13 May 2025

Disclaimer :

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.


Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

QR code to download Bajaj Broking App

9 lakh+ Users

icon-with-text

4.9 App Rating

icon-with-text

4 Languages

icon-with-text

₹7,300 Cr+ MTF Book

icon-with-text